Chicago, IL, United States of America

Brian Mattorano

This inventor holds 2 USPTO granted patents and 1 EPO patent. Top assignee: Medline Industries, Inc.. Active years: 2022-2024.


% Patents Active = 100.0

 

Average Co-Inventor Count = 3.0

ph-index = 1

Forward Citations = 1(Granted Patents)


Company Filing History:


Years Active: 2022-2024

Loading Chart...
Loading Chart...
2 patents (USPTO):Explore Patents

Title: Brian Mattorano: Innovator in Wound Treatment Solutions

Introduction

Brian Mattorano is a notable inventor based in Chicago, IL (US). He has made significant contributions to the field of wound treatment, holding 2 patents that focus on innovative solutions for promoting wound healing.

Latest Patents

His latest patents include a wound treatment containing collagen and a gelatin-reducing agent, as well as a method for promoting wound healing. The disclosed wound treatment features collagen and a gelatin-reducing agent, which can be present in a weight ratio of about 0.25:1 to about 4:1. Additionally, the wound dressing includes a substrate, collagen, and a gelatin-reducing agent. The method for promoting wound healing involves administering these components to a wound in need of treatment.

Career Highlights

Brian Mattorano is currently associated with Medline Industries, Inc., where he continues to develop and refine his innovative approaches to wound care. His work has the potential to significantly impact patient outcomes in medical settings.

Collaborations

Some of his notable coworkers include Debashish Chakravarthy and Anthony Frei, who contribute to the collaborative environment at Medline Industries, Inc.

Conclusion

Brian Mattorano's contributions to wound treatment through his patents and work at Medline Industries, Inc. highlight his commitment to advancing medical technology. His innovative solutions are paving the way for improved healing processes in patients.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…